Equities analysts predict that Onconova Therapeutics Inc (NASDAQ:ONTX) will post sales of $410,000.00 for the current quarter, according to Zacks. Two analysts have issued estimates for Onconova Therapeutics’ earnings, with the highest sales estimate coming in at $460,000.00 and the lowest estimate coming in at $350,000.00. Onconova Therapeutics posted sales of $170,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 141.2%. The business is scheduled to report its next quarterly earnings results on Monday, March 26th.
On average, analysts expect that Onconova Therapeutics will report full year sales of $410,000.00 for the current financial year, with estimates ranging from $1.10 million to $1.11 million. For the next fiscal year, analysts expect that the business will report sales of $5.75 million per share, with estimates ranging from $5.00 million to $6.50 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Onconova Therapeutics.
Onconova Therapeutics (NASDAQ:ONTX) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.02. Onconova Therapeutics had a negative net margin of 2,855.94% and a negative return on equity of 558.97%. The business had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.29 million.
A number of brokerages have issued reports on ONTX. Maxim Group reaffirmed a “buy” rating and set a $6.00 price objective on shares of Onconova Therapeutics in a report on Thursday, November 2nd. HC Wainwright reaffirmed a “buy” rating on shares of Onconova Therapeutics in a report on Thursday, November 9th. Finally, Zacks Investment Research raised shares of Onconova Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $7.33.
Shares of Onconova Therapeutics (ONTX) opened at $1.70 on Thursday. Onconova Therapeutics has a fifty-two week low of $1.21 and a fifty-two week high of $3.88. The stock has a market cap of $18.31, a P/E ratio of -0.56 and a beta of 0.10.
A number of institutional investors and hedge funds have recently made changes to their positions in ONTX. Vanguard Group Inc. boosted its position in shares of Onconova Therapeutics by 58.4% during the 2nd quarter. Vanguard Group Inc. now owns 87,940 shares of the biopharmaceutical company’s stock valued at $190,000 after acquiring an additional 32,418 shares during the last quarter. 683 Capital Management LLC boosted its position in shares of Onconova Therapeutics by 21.0% during the 3rd quarter. 683 Capital Management LLC now owns 375,000 shares of the biopharmaceutical company’s stock valued at $641,000 after acquiring an additional 65,140 shares during the last quarter. Sabby Management LLC boosted its position in shares of Onconova Therapeutics by 104.0% during the 2nd quarter. Sabby Management LLC now owns 784,000 shares of the biopharmaceutical company’s stock valued at $1,693,000 after acquiring an additional 399,640 shares during the last quarter. Finally, Tyndall Capital Partners L P boosted its position in shares of Onconova Therapeutics by 91.4% during the 2nd quarter. Tyndall Capital Partners L P now owns 997,022 shares of the biopharmaceutical company’s stock valued at $2,154,000 after acquiring an additional 476,190 shares during the last quarter. 25.44% of the stock is owned by institutional investors and hedge funds.
WARNING: “Onconova Therapeutics Inc (ONTX) Expected to Announce Quarterly Sales of $410,000.00” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/11/onconova-therapeutics-inc-ontx-expected-to-announce-quarterly-sales-of-410000-00.html.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
Get a free copy of the Zacks research report on Onconova Therapeutics (ONTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.